Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CLIAC Taking Steps To Publish CMS Survey Data On Lab Compliance

This article was originally published in The Gray Sheet

Executive Summary

Spurred by patient safety concerns, the Clinical Laboratory Improvement Advisory Committee will strive to publish CMS' lab survey results in CDC's Morbidity & Mortality Weekly Report

You may also be interested in...



CLIA-Waived Test Market Increasing As Public Health Concerns Loom

Rapid growth in the adoption of CLIA-waived laboratory tests is causing some unease regarding appropriate use of the tests

CLIA-Waived Test Market Increasing As Public Health Concerns Loom

Rapid growth in the adoption of CLIA-waived laboratory tests is causing some unease regarding appropriate use of the tests

GLP Guidance For Waived Testing Accepted; September Publication Planned

Manufacturers and distributors should endorse waived testing good laboratory practice guidelines in product information, Clinical Laboratory Improvement Advisory Committee members suggest

Related Content

UsernamePublicRestriction

Register

MT019788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel